149 results about "Papilloma" patented technology

An isolated protein sequence or peptide from the E2, E6 or E7 early coding region of human papillomavirus (HPV) that is soluble in an aqueous medium, and characterized by a relative paucity of tryptophan, methionine and cysteine residues, and a relative abundance of glycine and asparagine residues. Also disclosed are isolated protein sequences or peptides from the E2, E6 or E7 early coding regions of HPV 16 and 18 and methodologies for detecting or diagnosing cancer or cellular abnormalities. Detection or diagnosis of Cancer or cellular abnormalities may include detecting or diagnosing pre-cancerous or pre-malignant conditions, cervical dysplasia, cervical carcinoma, koilocytosis, hyperkeratosis, intraepithelial lesions, and other cancers. A methodology for detecting or diagnosing cancer or cellular abnormalities comprises the steps of (1) reacting a sample of body fluid or tissue with isolated protein sequences or peptides; (2) forming an antibody-peptide complex; and (3) detecting the antibody-peptide complex.

Disclosed herein are methods of detecting tumors, monitoring cancer therapy, and selectively inhibiting the proliferation and / or killing of cancer cells utilizing a papilloma pseudovirus or a papilloma virus-like particle (VLP).

A detector for detecting and simultaneously diagnosing at least one subtype of human papilloma viruses (HPV) contained in a biological sample is provided. The detector comprises: a carrier, a plurality of micro-dots immobilized on the carrier, wherein each micro-dot is for identifying one particular HPV subtype, and the HPV subtype is one selected from a group consisting of 39 different HPV subtypes; and at least one oligonucleotide sequence contained in each the micro-dot that is specific to the one particular HPV subtype, wherein the at least one oligonucleotide sequence serves as a detection probe that hybridizes specifically with an L1 gene sequence of the one particular HPV subtype to form a hybridization complex as a detection indicator, so that each micro-dot identifies one particular HPV subtype via a corresponding oligonucleotide of the one particular HPV subtype, and thereby detecting and simultaneously identifying subtypes of human papilloma viruses.

The invention relates to methods for producing papilloma-derived nanosphere particles that contain therapeutic, diagnostic, or other agents. The invention also provides nanosphere particle preparations that are useful for selectively delivering therapeutic, diagnostic, and / or other agents to cancer cells of subjects without eliciting a serotype-specific immunogenic response in the subjects.

The invention involves a papilloma pseudo-virus that can induce immune response after oral intake as well as its preparation. It is characterized in that HPV or BPV pseudo-virus are made by disrupting HPV-VLP or BPV-VLP, mixing them with plasmids (plasmids or DNA vaccine), and reassembling them into the pseudo-viruses (VLPs with plasmids inside). Oral administration of the pseudo-viruses will result in delivery to mucosal and systemic lymphoid tissues and induce immune responses for disease prevention and treatment. The pseudo-virus induces stronger immune response than DNA vaccines. Additionally, the pseudo-virus can be applied in gene therapy by bringing the therapeutic genes into lymphoid tissues in the human body.

[Problem] To provide a marker which serves as a measure for the treatment of breast cancer. [Solution] A kit for the diagnosis of breast cancer, which comprises an anti-LAT1 monoclonal antibody and / or a method for diagnosing breast cancer using an anti-LAT1 monoclonal antibody. Among mammary gland neoplastic lesions, ductal carcinoma in situ, which is malignant, undergoes the expression of LAT1 at a significantly high level compared with intraductal breast papilloma, which is benign. Therefore, an anti-LAT1 monoclonal antibody is useful for the discrimination between the two lesions. Further, LAT1 is expressed at a high level in most of triple-negative infiltrating carcinomas which are negative for all of ER, PgR and HER2 that are conventional molecular targeting markers for breast cancer and for which there is no proper molecular targeted therapy method. Therefore, LAT1 can be used as a novel molecular targeting marker for breast cancer. The expression of LAT1 can be diagnosed by the present immunohistological method, and the development of a molecular targeted therapy method in which LAT1 is targeted is effective.

The invention relates to a method of detecting HPV and determining HPV type.